Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
editorial
. 1997 Jul;123(7):365–369. doi: 10.1007/BF01240118

Regulation of p53 by protein kinase C during multi-stage carcinogenesis

Lucia Magnelli 1, Vincenzo Chiarugi 1,✉
PMCID: PMC12200320  PMID: 9260587

Conclusions

The hypothesis that we are currently trying to demonstrate is that of “initial cells” start the process of carcinogenesis by inducing G1-cyclin-dependent RB phosphorylation, E2F release and an increase of glycolysis, with the consequent sustained diacylglycerol production: PKC is down-regulated and p53 is maintained in its latent, inactive form; genomic damage progressively accumulates and the chromosomal aberrations may activate other oncogenes or deactivate tumor suppressors, leading to progression towards malignancy. This model agrees with the abnormally high level of diacylglycerol found in a variety of malignant tumors (Mills et al. 1993, Hendickse et al. 1995; Casamassima et al. 1996) (see Fig. 1B). To take an extreme view, not only are the presence, the loss, or the mutations sufficient screening data for the status of p53 in malignancy, but also the presence or the absence of phosphate groups at the carboxyl ends, as revealed by Pab421 antibody.

Footnotes

The Journal Cancer Research and Clinical Oncology occasionally publishes Editorials and Guest editorials on current and controversial problems in experimental and clinical oncology. These papers reflect the personal opinions of the authors. Readers should send any comments directly to the authors.

References

  1. Bischoff JR, Friedman PN, Marshak C, Prives C, Beach D (1990) Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87:4766–4771 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casamassima F, Pacini S, Dragotto A, Anichini M, Chiarugi V, Ruggiero M (1996) Intracellular diacylglycerol: a mitogenic second messenger proposable as a marker of transformation in squamous cell carcinoma of the lung. Lung Cancer 7:34–45 [DOI] [PubMed] [Google Scholar]
  3. Castagna M (1987) Phorbol esters as signal transducers and tumor promoters. Biol Cell 59:3–13 [DOI] [PubMed] [Google Scholar]
  4. Chiarugi V, Bruni P, Pasquali F, Magnelli L, Basi G, Ruggiero M, Farnararo M (1989a) Synthesis of diacylglycerol de novo is responsible for permanent activation and down-regulation of protein kinase C in transformed cells. Biochem Biophys Res Commun 164:816–823 [DOI] [PubMed] [Google Scholar]
  5. Chiarugi V, Magnelli L, Pasquali F, Basi G, Ruggiero M (1989b) Signal transduction in EJ-H-ras-transformed cells: de novo synthesis of diacylglycerol and subversion of agonist-stimulated inositol lipid metabolism. FEBS Lett 252:129–134 [DOI] [PubMed] [Google Scholar]
  6. Darville MI, Antoine IV, Mertens-Strijthagen JR, Dupriez VJ, Rousseau GG (1995) An E2F-dependent late-serum-response promoter in a gene that controls glycolysis. Oncogene 11:1509–1517 [PubMed] [Google Scholar]
  7. Delphin C, Baudier J (1994). The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of Ras transformed embryo fibroblasts growth arrest. J Biol Chem 269:29579–29587 [PubMed] [Google Scholar]
  8. Deppert W (1994) The ying and the yang of p53 in cellular proliferation. Cancer Biol 5:187–202 [PubMed] [Google Scholar]
  9. El-Deiry WS, Kern SE, Pietempol JA, Kinzler KW, Vogelstein B (1992) Human genomic DNA sequences define a consensus binding site for p53. Nature Genet 1:44–49 [DOI] [PubMed] [Google Scholar]
  10. Enamoto Y, Mamone Y, Meinardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Worg WW, Kamen R, Weichselbaum R, Kufe D (1995) Proteolytic activation of protein kinase C-d by ICE-like protease in apoptotic cells. EMBO J 14:6148–6156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Farber B, Kinzel V (1990) Distribution of phorbol ester TPA induced structural chromosomal aberration in HeLa cells. Carcinogenesis 11:2067–2070 [DOI] [PubMed] [Google Scholar]
  12. Farese RV, Konda TS, Davis JS, Standaert ML, Pollet RJ, Cooper DR (1987) Insulin rapidly increases diacylglycerol by activating de novo phosphatidic acid synthesis. Science 236:586–589 [DOI] [PubMed] [Google Scholar]
  13. Fiscella M, Zambrano N, Ullrich SJ, Unger T, Lin D, Cho B, Mercer E, Anderson CW, Apella E (1994) The carboxyl-terminal serine 392 phosphorylation site of human p53 is not required for wild type activities. Oncogene 9:3249–3252 [PubMed] [Google Scholar]
  14. Fujiki H, Suganuma M (1994) Tumour necrosis factor-α, a new tumour promoter, engendered by biochemical studies of okadaic acid. J Biochem 115:1–5 [DOI] [PubMed] [Google Scholar]
  15. Hecker D, Page G, Lohrum M, Weiland S, Scheidtmann KH (1996) Complex regulation of DNA-binding activity by p53 phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 12:953–961 [PubMed] [Google Scholar]
  16. Hendickse CW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP (1995) Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer. Br J Surg 82:475–478 [DOI] [PubMed] [Google Scholar]
  17. Hupp TR, Lane DP (1994) Regulation of cryptic sequence specific DNA binding protein function of p53 by protein kinases. Cold Spring Harbor Symp Quant Biol 59:195–206 [DOI] [PubMed] [Google Scholar]
  18. Hupp TR, Lane DP (1995) Two distinct signalling pathways activate the latent DNA-binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270:18165–18174 [DOI] [PubMed] [Google Scholar]
  19. Hupp TR, Sparks A, Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 80:237–245 [DOI] [PubMed] [Google Scholar]
  20. Jaken S (1996) Protein kinase C isoenzymes and substrates. Curr Opin Cell Biol 8:168–173 [DOI] [PubMed] [Google Scholar]
  21. Jamal S, Ziff EB (1995) Raf phosphorylates p53 in vitro and potentiates p53 transcriptional transactivation in vivo. Oncogene 10:2095–2101 [PubMed] [Google Scholar]
  22. Kikkawa U, Nishizuka Y (1986) The role of protein kinase C in transmembrane cell signaling. Annu Rev Cell Biol 2:149–178 [DOI] [PubMed] [Google Scholar]
  23. Krauter G, Von Der Lieth GW, Hecker E (1996) A new pharmacophore model for PKC activators based on structure activity studies and molecular modeling of tumour promoters TPA and 3-TI. Eur J Biochem (in press) [DOI] [PubMed]
  24. Lees-Miller SP, Sakaguchi K, Ullrich SJ, Apella E, Anderson CW (1992) Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the aminoterminal transactivation domain of human p53. Mol Cell Biol 12:5041–5046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Li W, Michieli P, Alimandi M, Lorenzi M, Wu Y, Wang LH, Heideran M, Pierce JH (1996) Expression of ATP-binding mutant of PKC-δ inhibits Sis-induced transformation in NIH-3T3 cells. Oncogene 13:731–737 [PubMed] [Google Scholar]
  26. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935 [DOI] [PubMed] [Google Scholar]
  27. Magnelli L, Cinelli M, Chiarugi V (1995) Phorbol esters attenuate the expression of p53 in cells treated with doxorubicin and protects tsp53/K562 from apoptosis. Biochem Biophys Res Commun 215:641–645 [DOI] [PubMed] [Google Scholar]
  28. Mills KJ, Reynolds SH, Smart RC (1993) Diacylglycerol is an effector of the clonal expansion of cells containing activated Ha-ras genes. Carcinogenesis 14:2645–2648 [DOI] [PubMed] [Google Scholar]
  29. Milne DM, Palmer RH, Meek DW (1992) Mutation of casein kinase II phosphorylation site abolishes the antiproliferative activity of p53. Nucleic Acids Res 20:5565–5570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Milne DM, Campbell DG, Caudwell FB, Meek DW (1994) Phosphorylation of tumor suppressor protein p53 by mitogen activated protein kinases. J Biol Chem 269:9253–9260 [PubMed] [Google Scholar]
  31. Milne DM, Campbell LE, Campbell DG, Meek DW (1995) p53 is phosphorylated in vitro and in vivo by the ultraviolet radiation-induced protein kinase characteristic of the c-jun kinase, JNK1. J Biol Chem 270:5511–5518 [DOI] [PubMed] [Google Scholar]
  32. Milne DM, McKendrick L, Jardine LJ, Deacon E, Lord JM, Meek DW (1996) Murine p53 is phosphorylated within the Pab421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester-o-tetradecanoylphorbol 13-acetate. Oncogene 13:205–211 [PubMed] [Google Scholar]
  33. Nishizuka Y (1989) The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. JAMA 262:1826–1833 [PubMed] [Google Scholar]
  34. Nishizuka Y (1995) Protein kinase C and lipid signalling for sustained cellular responses. FASEB J 9:484–496 [PubMed] [Google Scholar]
  35. Owens DM, Spalding JW, Tennant RW, Smart RC (1995) Genetic alterations cooperate with Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin. Cancer Res 55:3171–3178 [PubMed] [Google Scholar]
  36. Pitot HC (1996) Stage-specific gene expression during hepatocarcinogenesis in the rat. J Cancer Res Clin Oncol 122:2547–265 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rousseau G, Fisher Y, Guering MA, Marchand MJ, Testor X, Hue L (1988) De novo synthesis of DAG and regulation of glycolysis. Prog Cancer Res Ther 35:159–167 [Google Scholar]
  38. Ruggieri B, Caamano J, Goodrow TX, Di Rado M, Bianchi A, Trono D, Conti C, Klein-Szanto JP (1991) Alterations of p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res 51:6615–6621 [PubMed] [Google Scholar]
  39. Selivanova G, Wiman KG (1995) p53: a cell cycle regulator activated by DNA damage. Adv Cancer Res 66:143–180 [DOI] [PubMed] [Google Scholar]
  40. Skouv J, Jensen PO, Forchhammer J, Larsen JK, Lund LR (1994) Tumor-promoting phorbol ester transiently down-modulates the p53 level and blocks the cell cycle. Cell Growth Differ 5:329–340 [PubMed] [Google Scholar]
  41. Smart RC, Mills KJ, Hansen LA, Conney AH (1989) Synthetic lipid second messengersn-1,2-didecanoylglycerol: a complete tumor promoter in mouse skin. Cancer Res 49:4455–4458 [PubMed] [Google Scholar]
  42. Steward N, Hicks GG, Paraskevas F, Movat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109–115 [PubMed] [Google Scholar]
  43. Takenaka I, Morin F, Seizinger BR, Kley N (1995) Regulation of the sequence specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270:5405–5411 [DOI] [PubMed] [Google Scholar]
  44. Varshavsky A (1981) Phorbol ester dramatically increases incidence of methotrexate resistant mouse cells: possible mechanisms and relevance to tumour promotion. Cell 25:561–572 [DOI] [PubMed] [Google Scholar]
  45. Wang Y, Prives C (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376:88–91 [DOI] [PubMed] [Google Scholar]
  46. Watanabe T, Ono Y, Taniyama Y, Hazama K, Igarashi K, Ogita K, Kikkawa U, Nishizuka Y (1992) Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-d subspecies. Proc Natl Acad Sci 89:10159–10163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Xiong Y, Zhang H, Beach D (1992) D-type cyclins associate with multiple protein kinases and DNA replication and repair factor PCNA. Cell 71:505–514 [DOI] [PubMed] [Google Scholar]
  48. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES